Sanofi successfully prices EUR 1.5 billion of bond issue Paris, March 5, 2025. Sanofi announces that it has successfully priced its offering of ...
The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to ...
Berenberg analyst Luisa Hector raised the firm’s price target on Sanofi (SNY) to EUR 120 from EUR 115 and keeps a Buy rating on the ...
18h
Daily Maverick on MSNSA competition watchdog probes Novo Nordisk and Sanofi over insulinSouth Africa's Competition Commission is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...
A new analysis provides substantial evidence that paramagnetic rim lesions drive disability in MS and are targetable with a ...
In a case involving well-known anti-allergy drug Allegra, the Bombay High Court has imposed a fine on the defendants for ...
South Africa's competition watchdog launches a crucial investigation into pharmaceutical giants Novo Nordisk and Sanofi over ...
Posters presented at the Association of Cancer Care Centers opening session covered initiatives to boost clinical trial ...
With proper data governance, the pharma industry can improve patient-centricity in trials and bring lifesaving therapies to ...
Pharmalittle: We’re reading about lower Wegovy prices, a dispute over Merck’s Keytruda, and more
Novo Nordisk plans to offer its Wegovy weight loss drug at a reduced cost of $499 per month for cash-paying customers in the ...
Zandy Forbes’ biotech company MeiraGTx has developed targeted gene therapy methods to treat more than just genetic disorders.
3h
TipRanks on MSNNovavax (NVAX) Predicts Profitability by 2027 Despite Recent Stock DropNovavax ($NVAX) has recently seen a decrease in stock value, dropping after announcing Q4 results that missed revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results